301 related articles for article (PubMed ID: 26817451)
1. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
[TBL] [Abstract][Full Text] [Related]
2. Preoperative Neutrophil-to-Lymphocyte Ratio as a Predictive and Prognostic Factor for High-Grade Serous Ovarian Cancer.
Feng Z; Wen H; Bi R; Ju X; Chen X; Yang W; Wu X
PLoS One; 2016; 11(5):e0156101. PubMed ID: 27203425
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
Man YN; Wang YN; Hao J; Liu X; Liu C; Zhu C; Wu XZ
Int J Gynecol Cancer; 2015 Jan; 25(1):24-32. PubMed ID: 25347092
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of preoperative anemia, leukocytosis and thrombocytosis in chinese women with epithelial ovarian cancer.
Chen Y; Zhang L; Liu WX; Liu XY
Asian Pac J Cancer Prev; 2015; 16(3):933-9. PubMed ID: 25735385
[TBL] [Abstract][Full Text] [Related]
5. Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer.
Qiu J; Yu Y; Fu Y; Ye F; Xie X; Lu W
J Obstet Gynaecol Res; 2012 Apr; 38(4):651-7. PubMed ID: 22413879
[TBL] [Abstract][Full Text] [Related]
6. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer.
May T; Stewart JM; Bernardini MQ; Ferguson SE; Laframboise S; Jiang H; Rosen B
Int J Gynaecol Obstet; 2018 Feb; 140(2):247-252. PubMed ID: 29095487
[TBL] [Abstract][Full Text] [Related]
8. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
9. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
10. The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors.
Gungor T; Kanat-Pektas M; Sucak A; Mollamahmutoglu L
Arch Gynecol Obstet; 2009 Jan; 279(1):53-6. PubMed ID: 18470520
[TBL] [Abstract][Full Text] [Related]
11. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
12. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of preoperative plasma fibrinogen level and platelet count in resectable esophageal squamous cell carcinoma.
Wang J; Liu H; Shao N; Tan B; Song Q; Jia Y; Cheng Y
World J Surg Oncol; 2015 Apr; 13():157. PubMed ID: 25896470
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Postoperative Hormone Replacement Therapy on Prognosis of Patients with Serous Ovarian Carcinoma.
Zhang YL; Chen JH; Lu W; Li BL; Zhu QY; Wan XP
Chin Med J (Engl); 2016 Jun; 129(11):1316-21. PubMed ID: 27231169
[TBL] [Abstract][Full Text] [Related]
15. [CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction].
Gasowska-Bodnar A; Bodnar L; Wcisło GB; Jerzak MM; Szczylik C; Baranowski W
Ginekol Pol; 2008 Feb; 79(2):108-14. PubMed ID: 18510089
[TBL] [Abstract][Full Text] [Related]
16. The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer.
Lee M; Kim SW; Nam EJ; Yim GW; Kim S; Kim YT
Gynecol Oncol; 2011 Aug; 122(2):238-41. PubMed ID: 21531448
[TBL] [Abstract][Full Text] [Related]
17. Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer.
Muallem MZ; Parashkevova A; Almuheimid J; Richter R; Diab Y; Braicu EI; Sehouli J
Anticancer Res; 2017 Jun; 37(6):3157-3161. PubMed ID: 28551658
[TBL] [Abstract][Full Text] [Related]
18. Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival.
Cohen JG; Tran AQ; Rimel BJ; Cass I; Walsh CS; Karlan BY; Li AJ
Gynecol Oncol; 2014 Mar; 132(3):556-9. PubMed ID: 24423879
[TBL] [Abstract][Full Text] [Related]
19. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
Tate S; Hirai Y; Takeshima N; Hasumi K
Gynecol Oncol; 2005 Jan; 96(1):143-9. PubMed ID: 15589593
[TBL] [Abstract][Full Text] [Related]
20. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.
Crane EK; Sun CC; Ramirez PT; Schmeler KM; Malpica A; Gershenson DM
Gynecol Oncol; 2015 Jan; 136(1):25-9. PubMed ID: 25448453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
